Drug Trial Radar · NCT05547503
Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Oct 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Apr 11, 2023
Primary completion
Dec 4, 2024
Study completion May 14, 2025
Sponsor
- Lead sponsor
- Afasci IncIndustry
- Sponsor type
- Industry
- Collaborators
- Cognitive Research Corporation
- First posted
- Sep 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Phase I Part 1 (single ascending dose): Double-blind dosing will occur in healthy volunteers in 4 cohorts of 8 subjects each. Six subjects in each cohort will be randomized to receive AFA-281 and 2 subjects will be randomized to receive the matching placebo. At the end of the Part 1 study is to evaluate the safety and tolerability of AFA-281. Following completion of each cohort, bioanalytical analyses will be conducted to evaluate the pharmacokinetic profile. Phase I Part 2 (multiple dose for 14 days): Pending the results from Part 1, healthy volunteers will be administered AFA-281 for 14 to 21 consecutive days in 3 cohorts. At scheduled intervals after dosing, and at the end of the cohort's study period to evaluate the safety and tolerability and the pharmacokinetic profile of AFA-281.
Conditions
- Pain, Neuropathic
- Pain, Inflammatory
Interventions
AFA-281Drug
Part 1: AFA-281 will be administered as a single dose at 4 dose levels (TBD) Part 2: AFA-281 will be administered twice daily for 14 - 21 days at 3 dose levels (TBD)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-Related Adverse EventsTime frame: Predose and Up to 72 hours after dose
- Heart rateTime frame: Predose and Up to 72 hours after dose
- Body temperatureTime frame: Predose and Up to 72 hours after dose
- Blood PressureTime frame: Predose and Up to 72 hours after dose
- Electrocardiogram (ECG)Time frame: Pre-dose and up to 72 hours after dose
- Blood chemistryTime frame: Pre-dose and up to 72 hours after dose
- HematologyTime frame: Pre-dose and up to 72 hours after dose
- CoagulationTime frame: Pre-dose and up to 72 hours after dose
- UrinalysisTime frame: Pre-dose and up to 72 hours after dose
- Blood maximum plasma concentration (Cmax) of the study drugTime frame: Pre-dose and up to 72 hours after dose
- Blood study drug half-life (t1/2)Time frame: Pre-dose and up to 72 hours after dose
- Area under the plasma concentration versus time curve (AUC) of the study drugTime frame: Pre-dose and up to 72 hours after dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CenExcel CNS
Los Alamitos, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.